Product Name | Gastric Inhibitory Peptide (GIP), human |
Product Quantity | 5mg |
Catalog Number | LT1466 |
Molecular Weight | 4983.64 |
Formula | C226H338N60O66S1 |
Sequence | Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln |
Product Description | Gastric Inhibitory Peptide (GIP), also known as gastric inhibitory polypeptide, or glucose-dependent insulinotropic polypeptide, is a 42-amino-acid peptide hormone synthesized in and secreted from K cells in the intestinal epithelium. GIP secretion is primarily regulated by nutrients, especially fat. GIP exhibits potent incretin activity in rodents and human subjects. The primary action of GIP is the stimulation of glucose-dependent insulin secretion. GIP may also play a role in adipocyte biology. |
Scientific Background | Gastric Inhibitory Peptide (GIP), human is a synthetic research peptide in the glucose-dependent insulinotropic polypeptide (GIP) family. GIP is a 42-residue incretin hormone produced by intestinal K cells and acting through the class B GIP receptor. N-terminal processing is functionally important; truncated forms can show reduced agonism or antagonist properties, so exact residue numbering is critical. |
Research Applications | - GIP receptor assays
- incretin signaling studies
- DPP-IV processing research
- GIP fragment structure-activity studies
|
Experimental Notes | The exact sequence, residue range, species, terminal state, and chemical modifications should be matched to the intended assay. Fragmentation or processing can materially alter receptor selectivity, potency, aggregation, or enzymatic behavior. |
Selected References | - Glucose-dependent insulinotropic polypeptide (GIP)
- GIP receptor antagonists and truncated GIP peptides
|
